Floatz logo

Chimeric Antigen Receptor Modified T Cells Infusion

Lymphoma, B-Cell

Shanxi Bethune HospitalCell therapyPhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
73/ 100

Competitive context

316 Active assets in the Lymphoma, B-Cell cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
Odronextamab
University of Birmingham
Phase 3BBB
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Cytosin-Arabinosid
Children's Cancer Group, China
Phase 4BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB

View all 50 →

Same molecule, other indications

Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:

B Cell LymphomaDormant
BB
Indicative ·
71 / 100
View asset →
Non Hodgkin LymphomaDormant
BB
Indicative ·
67 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →